Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 10;14(22):5530.
doi: 10.3390/cancers14225530.

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Chiara Cattaneo  1 , Jon Salmanton-García  2   3 , Francesco Marchesi  4 , Shaimaa El-Ashwah  5 , Federico Itri  6 , Barbora Weinbergerová  7 , Maria Gomes Da Silva  8 , Michelina Dargenio  9 , Julio Dávila-Valls  10 , Sonia Martín-Pérez  10 , Francesca Farina  11 , Jaap Van Doesum  12 , Toni Valković  13   14   15 , Caroline Besson  16 , Christian Bjørn Poulsen  17 , Alberto López-García  18 , Pavel Žák  19 , Martin Schönlein  20 , Klára Piukovics  21 , Ozren Jaksic  22 , Alba Cabirta  23   24 , Natasha Ali  25 , Uluhan Sili  26 , Nicola Fracchiolla  27 , Giulia Dragonetti  28 , Tatjana Adžić-Vukičević  29 , Monia Marchetti  30 , Marina Machado  31 , Andreas Glenthøj  32 , Olimpia Finizio  33 , Fatih Demirkan  34 , Ola Blennow  35 , Maria Chiara Tisi  36 , Ali S Omrani  37 , Milan Navrátil  38 , Zdeněk Ráčil  39 , Jan Novák  40 , Gabriele Magliano  41 , Moraima Jiménez  42   43 , Carolina Garcia-Vidal  44 , Nurettin Erben  45 , Maria Ilaria Del Principe  46 , Caterina Buquicchio  47 , Rui Bergantim  48 , Josip Batinić  49   50   51 , Murtadha Al-Khabori  52 , Luisa Verga  53   54 , Tomáš Szotkowski  55 , Michail Samarkos  56 , Irati Ormazabal-Vélez  57 , Stef Meers  58 , Johan Maertens  59 , László Imre Pinczés  60 , Martin Hoenigl  61   62   63 , Ľuboš Drgoňa  64 , Annarosa Cuccaro  65 , Yavuz M Bilgin  66 , Avinash Aujayeb  67 , Laman Rahimli  2   3 , Stefanie Gräfe  2   3   68 , Mariarita Sciumè  27 , Miloš Mladenović  29   69 , Gökçe Melis Çolak  26 , Maria Vittoria Sacchi  30 , Anna Nordlander  35 , Caroline Berg Venemyr  32 , Michaela Hanáková  39 , Nicole García-Poutón  43 , Ziad Emarah  5 , Giovanni Paolo Maria Zambrotta  52   53 , Raquel Nunes Rodrigues  8 , Raul Cordoba  18 , Gustavo-Adolfo Méndez  70 , Monika M Biernat  71 , Oliver A Cornely  2   3   72   73 , Livio Pagano  28   74
Affiliations

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Chiara Cattaneo et al. Cancers (Basel). .

Abstract

Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

Keywords: COVID-19; haematological malignancy onset; outcome; prognostic factors; treatment.

PubMed Disclaimer

Conflict of interest statement

The funder of the study had no role in study design, data analysis, interpretation, or writing of the report. All authors had full access to the data and had final responsibility for the decision to submit for publication.

Figures

Figure 1
Figure 1
Overall survival probability. (a) Cohort. (b) Patients by malignancy.
Figure 1
Figure 1
Overall survival probability. (a) Cohort. (b) Patients by malignancy.
Figure 2
Figure 2
30-day survival probability of treated vs. untreated patients.
See this image and copyright information in PMC

References

    1. Pagano L., Salmanton-García J., Marchesi F., Busca A., Corradini P., Hoenigl M., Klimko N., Koehler P., Pagliuca A., Passamonti F., et al. COVID-19 infection in adult patients with hematological malignancies: A European Hematology Association Survey (EPICOVIDEHA) J. Hematol. Oncol. 2021;14:168. doi: 10.1186/s13045-021-01177-0. - DOI - PMC - PubMed
    1. García-Suárez J., de la Cruz J., Cedillo Á., Llamas P., Duarte R., Jiménez-Yuste V., Hernández-Rivas J.Á., Gil-Manso R., Kwon M., Sánchez-Godoy P., et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study. J. Hematol. Oncol. 2020;13:133. doi: 10.1186/s13045-020-00970-7. - DOI - PMC - PubMed
    1. Cattaneo C., Daffini R., Pagani C., Salvetti M., Mancini V., Borlenghi E., D’Adda M., Oberti M., Paini A., De Ciuceis C., et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020;126:5069–5076. doi: 10.1002/cncr.33160. - DOI - PubMed
    1. Zeidan A.M., Boddu P.C., Patnaik M.M., Bewersdorf J.P., Stahl M., Rampal R.K., Shallis R., Steensma D.P., Savona M.R., Sekeres M.A., et al. Special considerations in the management of adult patients with acute leukemias and myeloid neoplasms in the COVID-19 era: Recommendations from a panel of international experts. Lancet Haematol. 2020;7:e601–e612. doi: 10.1016/S2352-3026(20)30205-2. - DOI - PMC - PubMed
    1. Marchesi F., Salmanton-García J., Emarah Z., Piukovics K., Nucci M., López-García A., Ráčil Z., Farina F., Popova M., Zompi S., et al. COVID-19 in adult acute myeloid leukemia patients: A long-term followup study from the European Hematology Association survey (EPICOVIDEHA) Haematologica. 2022. online ahead of print . - DOI - PMC - PubMed

LinkOut - more resources